Effect of Orka in Diabetes

Phase 3

Conditions: Type II Diabetes Mellitus.
Type 2 diabetes mellitus

Registration Number: IRCT20120112008712N2

Lead Sponsor: Maragheh University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 80

Inclusion Criteria

All patients with at least 2 years of type 2 DM
Using oral hypoglycemic agents but not insulin
Fasting blood sugar (FBS) 150-200 mg/dl and HbA1c 7.5-9%
Age between 40 and 60 years

Exclusion Criteria

unwillingness to participation;
Pregnancy and lactation and in women of childbearing age without reliable contraceptive methods;
Tobacco smokers and alcohol consumers and patients who tend to change their diet or exercise program.
Any serious comorbidities (including renal failure, chronic hepatic failure, untreated heart failure, pulmonary infections and proliferative retinopathy), active neoplastic disease, a history of cancer less than 5 years, and depression

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting blood Suger. Timepoint: At the beginning and the end of study (60th day). Method of measurement: Lab Kit.;Lipid Profile. Timepoint: At the beginning and the end of study (60th day). Method of measurement: Lab Kit.

Secondary Outcome Measures

Name	Time	Method
HOMA-IR. Timepoint: At the beginnings and the end of study (90th day). Method of measurement: Lab Kit and Software calculation.;Hb A1C. Timepoint: At the beginnings and the end of study (90th day). Method of measurement: Lab kit.;Body Mass Index. Timepoint: At the beginnings and the end of study (90th day). Method of measurement: Scales and tape measure.;C reactive Protoein. Timepoint: At the beginnings and the end of study (90th day). Method of measurement: lab kit.